Preventing Osteoporosis, Sarcopenia and Obesity to Care about Quality of Life

Cacciatore, Stefano

doi:10.4235/agmr.22.0158

Cited by 10 publications

(10 citation statements)

References 30 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…To our knowledge, there are no published studies analyzing QoL in SO using the ESPEN/EASO criteria, although there are studies reporting that the loss of QoL in SO assessed with other criteria is high [ 11 , 57 , 58 ]. Comorbidities often associated with SO, such as osteoporosis or cardiovascular risk associated with obesity, together with changes in the aging process itself, could have an effect in this regard [ 59 ]. Previous studies indicate that SO is even associated with alterations in the social environment, given that pain, fear of falls, and fractures all limit activity, which leads to a loss of quality of life [ 60 , 61 ].…”

Section: Discussionmentioning

confidence: 99%

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Fonfría-Vivas¹,

Pérez‐Ros²,

Barrachina-Igual³

et al. 2023

Aging Clin Exp Res

View full text Add to dashboard Cite

Background Health-related quality of life (HRQoL) may be impaired in the presence of sarcopenia. Since a specific quality of life questionnaire became available for sarcopenia (SarQol), cutoffs to screen for this condition have been proposed, prompting the need to assess them in different populations. Due to the lack of consensus on diagnostic criteria, the tool has not yet been analyzed in screening for sarcopenic obesity. Aim Our aim is to measure the SarQoL’s metric properties and establish a cutoff in QoL assessments that could be used along the diagnostic pathway for sarcopenia and sarcopenic obesity in community-dwelling older women. Methods This cross-sectional study assessed women aged ≥ 70 years using the SarQol, sarcopenia criteria (EWGSOP2) and sarcopenic obesity criteria (ESPEN/EASO). Cutoffs for the SarQol were defined with a receiver-operating characteristics (ROC) curve, and sensitivity and specificity were analyzed. Results Of the 95 included women (mean age 76.0 years, standard deviation [SD] 5.7), 7.3% (n = 7) were classified as having sarcopenic obesity, 22.1% (n = 21) as having sarcopenia, and 70.5% (n = 67) as not having sarcopenia. The total SarQol score was higher in women without sarcopenia (66.5 SD 16.2) versus those with sarcopenia (56.6 SD 15.6) and sarcopenic obesity (45.1 SD 7.9). A cutoff of ≤ 60 points is proposed for sarcopenia screening (area under the ROC curve [AUC] 0.67; 95% confidence interval [CI] 0.53–0.80; sensitivity 61.9%; specificity 62%), and ≤ 50 points for sarcopenic obesity (AUC 0.85; 95% CI 0.74–0.95; sensitivity 71.4%; specificity 76.9%). Conclusions Quality of life is compromised in women with sarcopenia and especially in those with sarcopenic obesity. The SarQol could be useful in screening for these conditions, providing insight into health-related quality of life in older people with sarcopenia.

show abstract

Section: Discussionmentioning

confidence: 99%

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Fonfría-Vivas¹,

Pérez‐Ros²,

Barrachina-Igual³

et al. 2023

Aging Clin Exp Res

View full text Add to dashboard Cite

show abstract

“…Yi Zhan et al [11] con rmed that BMI is a protective factor for postmenopausal osteoporosis, but this literature did not specify the grade of BMI because the effects of low and high BMI on postmenopausal osteoporosis in women are different, and this meta-analysis proved that high BMI is a risk factor for concurrent osteoporosis in menopausal women, which may be because body mass index mainly re ects overall fatness and thinness. A proper body mass index can stimulate weight-bearing bone growth and facilitate bone health [12] , while obesity can lead to a decrease in bone cells and also destroy bone cells through in ammatory factors, leading to osteoporosis [13] , Xia Xia-Mei et al con rmed that BMI is a protective factor against osteoporosis in elderly men, while Wang Yu-He et al con rmed that there is no correlation between BMI and risk factors for primary osteoporosis. The results of domestic and international studies are somewhat divergent regarding the correlation between BMI and risk factors for primary osteoporosis because the effects of different levels of BMI on primary osteoporosis are different.…”

Section: Discussionmentioning

confidence: 99%

Meta-analysis of the correlation between BMI and risk factors for osteoporosis

Gong,

Cai,

2023

Preprint

View full text Add to dashboard Cite

Objectives: The purpose of this meta-analysis is to assess whether there is an association between BMI and osteoporosis. Methods: Domestic and foreign databases were searched for case-control studies published from 1990.1.1. to 2022.12.31, they use medical subject headings (MeSH) and keywords. All statistical analyses were performed using Review Manager 5.3. If I2 <50%, a fixed-effects model was adopted. If I2> 50% (which indicated great heterogeneity), a random-effects model was adopted. Results: This meta-analysis included 18 case-control studies covering 9078 individuals, published between 1990 and 2022. The pooling analysis shows that low BMI is a risk factor for osteoporosis complicated by type 2 diabetes, high BMI is a risk factor for osteoporosis complicated by menopausal women, and low BMI is a risk factor for primary osteoporosis. The correlation between normal and high BMI and primary osteoporosis cannot be demonstrated yet; BMI is a risk factor for osteoporosis in patients with frequent glucocorticoid use or COPD, and the correlation between BMI and risk factors for osteoporosis in stroke patients cannot be demonstrated yet. Conclusions: Our meta-analysis shows that low BMI is a risk factor for osteoporosis complicated by type 2 diabetes and primary osteoporosis, high BMI is a risk factor for osteoporosis complicated by menopausal women, and BMI is a risk factor for osteoporosis in patients with frequent glucocorticoid use or COPD. This provides a theoretical basis for the prevention of osteoporosis in clinical practice.

show abstract

“…[22,23] When conducting longitudinal observations in community-dwelling older individuals, sarcopenia has been reported to be associated with various adverse outcomes, including overall mortality, falls, fractures, physical and cognitive function decline, impairment of activities of daily living, reduced quality of life, and admission to care facilities due to functional decline. [12,[24][25][26] Furthermore, in studies involving patients admitted to hospitals for various individual diseases, sarcopenia has been found to predict complications during inpatient or surgical treatments. [27] This association has been actively reported in clinical scenarios such as cardiac surgery, liver transplantation, kidney transplantation, various solid tumor surgeries, and adjuvant/palliative chemotherapy for cancer.…”

Section: Epidemiologymentioning

confidence: 99%

Sarcopenia as the Mobility Phenotype of Aging: Clinical Implications

Ji,

Jung,

Baek

et al. 2024

J Bone Metab

View full text Add to dashboard Cite

Sarcopenia, which is characterized by an age-related decline in muscle mass and function, poses significant challenges to geriatric care. Its definition has evolved from muscle-specific criteria to include muscle mass, muscle function, and physical performance, recognizing sarcopenia as a physical frailty. Sarcopenia is associated with adverse outcomes, including mortality, falls, fractures, cognitive decline, and admission to long-term care facilities. Neuromechanical factors, protein-energy balance, and muscle protein synthesis-breakdown mechanisms contribute to its pathophysiology. The identification of sarcopenia involves screening tests and a comprehensive assessment of muscle mass, strength, and physical function. Clinical approaches aligned with the principles of comprehensive geriatric assessment prioritize patient-centered care. This assessment aids in identifying issues related to activities of daily living, cognition, mood, nutrition, and social support, alongside other aspects. The general approach to factors underlying muscle loss and functional decline in patients with sarcopenia includes managing chronic diseases and evaluating administered medications, with interventions including exercise and nutrition, as well as evolving pharmacological options. Ongoing research targeting pathways, such as myostatin-activin and exercise mimetics, holds promise for pharmacological interventions. In summary, sarcopenia requires a multifaceted approach, acknowledging its complex etiology and tailoring interventions to individual patient needs.

show abstract

Preventing Osteoporosis, Sarcopenia and Obesity to Care about Quality of Life

Cited by 10 publications

References 30 publications

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Assessing quality of life with SarQol is useful in screening for sarcopenia and sarcopenic obesity in older women

Meta-analysis of the correlation between BMI and risk factors for osteoporosis

Sarcopenia as the Mobility Phenotype of Aging: Clinical Implications

Contact Info

Product

Resources

About